Global Community-acquired Bacterial Pneumonia Market Size, Status and Forecast 2021-2027

SKU ID : QYR-19178339 | Publishing Date : 16-Sep-2021 | No. of pages : 106

Detailed TOC of Global Community-acquired Bacterial Pneumonia Market Size, Status and Forecast 2021-2027

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Pleuromutilin Antibiotic
        1.2.3 Cephalosporin
        1.2.4 Glycylcycline
        1.2.5 Oxazolidinone
        1.2.6 Ketolide
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Community-acquired Bacterial Pneumonia Market Share by Distribution Channel: 2016 VS 2021 VS 2027
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
    2.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2016-2027)
    2.2 Community-acquired Bacterial Pneumonia Growth Trends by Regions
        2.2.1 Community-acquired Bacterial Pneumonia Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Community-acquired Bacterial Pneumonia Historic Market Share by Regions (2016-2021)
        2.2.3 Community-acquired Bacterial Pneumonia Forecasted Market Size by Regions (2022-2027)
    2.3 Community-acquired Bacterial Pneumonia Industry Dynamic
        2.3.1 Community-acquired Bacterial Pneumonia Market Trends
        2.3.2 Community-acquired Bacterial Pneumonia Market Drivers
        2.3.3 Community-acquired Bacterial Pneumonia Market Challenges
        2.3.4 Community-acquired Bacterial Pneumonia Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue
        3.1.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue (2016-2021)
        3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2016-2021)
    3.2 Global Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Community-acquired Bacterial Pneumonia Revenue
    3.4 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio
        3.4.1 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Community-acquired Bacterial Pneumonia Revenue in 2020
    3.5 Community-acquired Bacterial Pneumonia Key Players Head office and Area Served
    3.6 Key Players Community-acquired Bacterial Pneumonia Product Solution and Service
    3.7 Date of Enter into Community-acquired Bacterial Pneumonia Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Community-acquired Bacterial Pneumonia Breakdown Data by Type
    4.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2016-2021)
    4.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2022-2027)

5 Community-acquired Bacterial Pneumonia Breakdown Data by Distribution Channel
    5.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Distribution Channel (2016-2021)
    5.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Distribution Channel (2022-2027)

6 North America
    6.1 North America Community-acquired Bacterial Pneumonia Market Size (2016-2027)
    6.2 North America Community-acquired Bacterial Pneumonia Market Size by Type
        6.2.1 North America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021)
        6.2.2 North America Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027)
        6.2.3 North America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2027)
    6.3 North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel
        6.3.1 North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021)
        6.3.2 North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027)
        6.3.3 North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2027)
    6.4 North America Community-acquired Bacterial Pneumonia Market Size by Country
        6.4.1 North America Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021)
        6.4.2 North America Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Community-acquired Bacterial Pneumonia Market Size (2016-2027)
    7.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type
        7.2.1 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021)
        7.2.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027)
        7.2.3 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2016-2027)
    7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel
        7.3.1 Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021)
        7.3.2 Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027)
        7.3.3 Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2027)
    7.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country
        7.4.1 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021)
        7.4.2 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2016-2027)
    8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type
        8.2.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type (2016-2027)
    8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel
        8.3.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021)
        8.3.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027)
        8.3.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2027)
    8.4 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region
        8.4.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Community-acquired Bacterial Pneumonia Market Size (2016-2027)
    9.2 Latin America Community-acquired Bacterial Pneumonia Market Size by Type
        9.2.1 Latin America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021)
        9.2.2 Latin America Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027)
        9.2.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2027)
    9.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel
        9.3.1 Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021)
        9.3.2 Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027)
        9.3.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2027)
    9.4 Latin America Community-acquired Bacterial Pneumonia Market Size by Country
        9.4.1 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021)
        9.4.2 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2016-2027)
    10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type
        10.2.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2016-2027)
    10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel
        10.3.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021)
        10.3.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027)
        10.3.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2027)
    10.4 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country
        10.4.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Nabriva Therapeutics
        11.1.1 Nabriva Therapeutics Company Details
        11.1.2 Nabriva Therapeutics Business Overview
        11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Introduction
        11.1.4 Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.1.5 Nabriva Therapeutics Recent Development
    11.2 Paratek Pharmaceuticals
        11.2.1 Paratek Pharmaceuticals Company Details
        11.2.2 Paratek Pharmaceuticals Business Overview
        11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
        11.2.4 Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.2.5 Paratek Pharmaceuticals Recent Development
    11.3 Melinta Therapeutics
        11.3.1 Melinta Therapeutics Company Details
        11.3.2 Melinta Therapeutics Business Overview
        11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Introduction
        11.3.4 Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.3.5 Melinta Therapeutics Recent Development
    11.4 Allergan plc
        11.4.1 Allergan plc Company Details
        11.4.2 Allergan plc Business Overview
        11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Introduction
        11.4.4 Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.4.5 Allergan plc Recent Development
    11.5 Bayer AG
        11.5.1 Bayer AG Company Details
        11.5.2 Bayer AG Business Overview
        11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Introduction
        11.5.4 Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.5.5 Bayer AG Recent Development
    11.6 Lupin Pharmaceuticals
        11.6.1 Lupin Pharmaceuticals Company Details
        11.6.2 Lupin Pharmaceuticals Business Overview
        11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
        11.6.4 Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.6.5 Lupin Pharmaceuticals Recent Development
    11.7 Mylan N.V.
        11.7.1 Mylan N.V. Company Details
        11.7.2 Mylan N.V. Business Overview
        11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Introduction
        11.7.4 Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.7.5 Mylan N.V. Recent Development
    11.8 Sanofi S.A.
        11.8.1 Sanofi S.A. Company Details
        11.8.2 Sanofi S.A. Business Overview
        11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Introduction
        11.8.4 Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.8.5 Sanofi S.A. Recent Development
    11.9 Pfizer Inc.
        11.9.1 Pfizer Inc. Company Details
        11.9.2 Pfizer Inc. Business Overview
        11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Introduction
        11.9.4 Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.9.5 Pfizer Inc. Recent Development
    11.10 Dainippon Sumitomo Pharma
        11.10.1 Dainippon Sumitomo Pharma Company Details
        11.10.2 Dainippon Sumitomo Pharma Business Overview
        11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Introduction
        11.10.4 Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.10.5 Dainippon Sumitomo Pharma Recent Development
    11.11 Takeda Pharmaceutical Company Limited
        11.11.1 Takeda Pharmaceutical Company Limited Company Details
        11.11.2 Takeda Pharmaceutical Company Limited Business Overview
        11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Introduction
        11.11.4 Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.11.5 Takeda Pharmaceutical Company Limited Recent Development
    11.12 Basilea Pharmaceutica International AG
        11.12.1 Basilea Pharmaceutica International AG Company Details
        11.12.2 Basilea Pharmaceutica International AG Business Overview
        11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Introduction
        11.12.4 Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021)
        11.12.5 Basilea Pharmaceutica International AG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Figures, Tables and Charts Available in Global Community-acquired Bacterial Pneumonia Market Size, Status and Forecast 2021-2027

List of Tables
    Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Pleuromutilin Antibiotic
    Table 3. Key Players of Cephalosporin
    Table 4. Key Players of Glycylcycline
    Table 5. Key Players of Oxazolidinone
    Table 6. Key Players of Ketolide
    Table 7. Key Players of Others
    Table 8. Global Community-acquired Bacterial Pneumonia Market Size Growth by Distribution Channel (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 10. Global Community-acquired Bacterial Pneumonia Market Size by Regions (2016-2021) & (US$ Million)
    Table 11. Global Community-acquired Bacterial Pneumonia Market Share by Regions (2016-2021)
    Table 12. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 13. Global Community-acquired Bacterial Pneumonia Market Share by Regions (2022-2027)
    Table 14. Community-acquired Bacterial Pneumonia Market Trends
    Table 15. Community-acquired Bacterial Pneumonia Market Drivers
    Table 16. Community-acquired Bacterial Pneumonia Market Challenges
    Table 17. Community-acquired Bacterial Pneumonia Market Restraints
    Table 18. Global Community-acquired Bacterial Pneumonia Revenue by Players (2016-2021) & (US$ Million)
    Table 19. Global Community-acquired Bacterial Pneumonia Market Share by Players (2016-2021)
    Table 20. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2020)
    Table 21. Ranking of Global Top Community-acquired Bacterial Pneumonia Companies by Revenue (US$ Million) in 2020
    Table 22. Global 5 Largest Players Market Share by Community-acquired Bacterial Pneumonia Revenue (CR5 and HHI) & (2016-2021)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Community-acquired Bacterial Pneumonia Product Solution and Service
    Table 25. Date of Enter into Community-acquired Bacterial Pneumonia Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 28. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2016-2021)
    Table 29. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 30. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 31. Global Community-acquired Bacterial Pneumonia Market Size Share by Distribution Channel (2016-2021) & (US$ Million)
    Table 32. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Distribution Channel (2016-2021)
    Table 33. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Distribution Channel (2022-2027) (US$ Million)
    Table 34. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Distribution Channel (2022-2027) & (US$ Million)
    Table 35. North America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 36. North America Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027) & (US$ Million)
    Table 37. North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021) (US$ Million)
    Table 38. North America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027) & (US$ Million)
    Table 39. North America Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021) & (US$ Million)
    Table 40. North America Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027) & (US$ Million)
    Table 41. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 42. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027) & (US$ Million)
    Table 43. Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021) (US$ Million)
    Table 44. Europe Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027) & (US$ Million)
    Table 45. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021) & (US$ Million)
    Table 46. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021) (US$ Million)
    Table 50. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027) & (US$ Million)
    Table 51. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2016-2021) & (US$ Million)
    Table 52. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2022-2027) & (US$ Million)
    Table 53. Latin America Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 54. Latin America Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027) & (US$ Million)
    Table 55. Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021) (US$ Million)
    Table 56. Latin America Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027) & (US$ Million)
    Table 57. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021) & (US$ Million)
    Table 58. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2016-2021) (US$ Million)
    Table 62. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Distribution Channel (2022-2027) & (US$ Million)
    Table 63. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2016-2021) & (US$ Million)
    Table 64. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2022-2027) & (US$ Million)
    Table 65. Nabriva Therapeutics Company Details
    Table 66. Nabriva Therapeutics Business Overview
    Table 67. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product
    Table 68. Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 69. Nabriva Therapeutics Recent Development
    Table 70. Paratek Pharmaceuticals Company Details
    Table 71. Paratek Pharmaceuticals Business Overview
    Table 72. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product
    Table 73. Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 74. Paratek Pharmaceuticals Recent Development
    Table 75. Melinta Therapeutics Company Details
    Table 76. Melinta Therapeutics Business Overview
    Table 77. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product
    Table 78. Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 79. Melinta Therapeutics Recent Development
    Table 80. Allergan plc Company Details
    Table 81. Allergan plc Business Overview
    Table 82. Allergan plc Community-acquired Bacterial Pneumonia Product
    Table 83. Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 84. Allergan plc Recent Development
    Table 85. Bayer AG Company Details
    Table 86. Bayer AG Business Overview
    Table 87. Bayer AG Community-acquired Bacterial Pneumonia Product
    Table 88. Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 89. Bayer AG Recent Development
    Table 90. Lupin Pharmaceuticals Company Details
    Table 91. Lupin Pharmaceuticals Business Overview
    Table 92. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product
    Table 93. Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 94. Lupin Pharmaceuticals Recent Development
    Table 95. Mylan N.V. Company Details
    Table 96. Mylan N.V. Business Overview
    Table 97. Mylan N.V. Community-acquired Bacterial Pneumonia Product
    Table 98. Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 99. Mylan N.V. Recent Development
    Table 100. Sanofi S.A. Company Details
    Table 101. Sanofi S.A. Business Overview
    Table 102. Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 103. Sanofi S.A. Recent Development
    Table 104. Pfizer Inc. Company Details
    Table 105. Pfizer Inc. Business Overview
    Table 106. Pfizer Inc. Community-acquired Bacterial Pneumonia Product
    Table 107. Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 108. Pfizer Inc. Recent Development
    Table 109. Dainippon Sumitomo Pharma Company Details
    Table 110. Dainippon Sumitomo Pharma Business Overview
    Table 111. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product
    Table 112. Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 113. Dainippon Sumitomo Pharma Recent Development
    Table 114. Takeda Pharmaceutical Company Limited Company Details
    Table 115. Takeda Pharmaceutical Company Limited Business Overview
    Table 116. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product
    Table 117. Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 118. Takeda Pharmaceutical Company Limited Recent Development
    Table 119. Basilea Pharmaceutica International AG Company Details
    Table 120. Basilea Pharmaceutica International AG Business Overview
    Table 121. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product
    Table 122. Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2016-2021) & (US$ Million)
    Table 123. Basilea Pharmaceutica International AG Recent Development
    Table 124. Research Programs/Design for This Report
    Table 125. Key Data Information from Secondary Sources
    Table 126. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Community-acquired Bacterial Pneumonia Market Share by Type: 2020 VS 2027
    Figure 2. Pleuromutilin Antibiotic Features
    Figure 3. Cephalosporin Features
    Figure 4. Glycylcycline Features
    Figure 5. Oxazolidinone Features
    Figure 6. Ketolide Features
    Figure 7. Others Features
    Figure 8. Global Community-acquired Bacterial Pneumonia Market Share by Distribution Channel: 2020 VS 2027
    Figure 9. Hospital Pharmacies Case Studies
    Figure 10. Retail Pharmacies Case Studies
    Figure 11. Online Pharmacies Case Studies
    Figure 12. Community-acquired Bacterial Pneumonia Report Years Considered
    Figure 13. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 14. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 15. Global Community-acquired Bacterial Pneumonia Market Share by Regions: 2020 VS 2027
    Figure 16. Global Community-acquired Bacterial Pneumonia Market Share by Regions (2022-2027)
    Figure 17. Global Community-acquired Bacterial Pneumonia Market Share by Players in 2020
    Figure 18. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2020
    Figure 19. The Top 10 and 5 Players Market Share by Community-acquired Bacterial Pneumonia Revenue in 2020
    Figure 20. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2016-2021)
    Figure 21. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2022-2027)
    Figure 22. North America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. North America Community-acquired Bacterial Pneumonia Market Share by Type (2016-2027)
    Figure 24. North America Community-acquired Bacterial Pneumonia Market Share by Distribution Channel (2016-2027)
    Figure 25. North America Community-acquired Bacterial Pneumonia Market Share by Country (2016-2027)
    Figure 26. United States Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Canada Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Europe Community-acquired Bacterial Pneumonia Market Share by Type (2016-2027)
    Figure 30. Europe Community-acquired Bacterial Pneumonia Market Share by Distribution Channel (2016-2027)
    Figure 31. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2016-2027)
    Figure 32. Germany Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. France Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. U.K. Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Italy Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Russia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Nordic Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Type (2016-2027)
    Figure 40. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Distribution Channel (2016-2027)
    Figure 41. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2016-2027)
    Figure 42. China Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Japan Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. South Korea Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Southeast Asia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. India Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Australia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Latin America Community-acquired Bacterial Pneumonia Market Share by Type (2016-2027)
    Figure 50. Latin America Community-acquired Bacterial Pneumonia Market Share by Distribution Channel (2016-2027)
    Figure 51. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2016-2027)
    Figure 52. Mexico Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Brazil Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Type (2016-2027)
    Figure 56. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Distribution Channel (2016-2027)
    Figure 57. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2016-2027)
    Figure 58. Turkey Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. UAE Community-acquired Bacterial Pneumonia Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. Nabriva Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 62. Paratek Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 63. Melinta Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 64. Allergan plc Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 65. Bayer AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 66. Lupin Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 67. Mylan N.V. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 68. Sanofi S.A. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 69. Pfizer Inc. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 70. Dainippon Sumitomo Pharma Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 71. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 72. Basilea Pharmaceutica International AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2016-2021)
    Figure 73. Bottom-up and Top-down Approaches for This Report
    Figure 74. Data Triangulation
    Figure 75. Key Executives Interviewed

Keyplayers in Global Community-acquired Bacterial Pneumonia Market Size, Status and Forecast 2021-2027

Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG

REQUEST SUMMARY

Request Sample

Pre-order Enquiry

Request Discount

Contact Information

24/7 Research Support

Phone: +1 424 253 0807

[email protected]